Takeaways

#
  • Sohn saw a contrarian case for health care in fund outflows, weak past relative returns and improvement in equipment and life sciences names.
  • Strazza cited 2020–21 as an example of XLV gaining in price while trailing the S&P 500.
  • Sohn thought strong index momentum could support the following year even as narrower participation left room for a near-term setback.

On the morning of February 6, 2024, Eli Lilly had the earnings news and the higher stock price. Todd Sohn was interested in the health care companies that had attracted less money and attention. He had expected some of the enthusiasm for Lilly to spread to the equipment makers. That rotation hadn't played out the way he expected, he told Spencer Israel, JC Parets and Steve Strazza, but a handful of equipment and life sciences charts had started improving.

A reversal didn't require Lilly’s business to deteriorate

By Sohn’s measures, investors had pulled money out of health care funds, and the sector’s rolling performance relative to the market ranked in its bottom historical decile. A portfolio manager looking beyond the largest technology and communications companies had several choices. Utilities were struggling, and consumer staples had problems of their own. Health care offered Sohn something different: a group investors had largely passed over, with stocks such as Abbott, Medtronic and Danaher beginning to perk up.

Strazza put the choice plainly. If the XLV health care ETF broke out, why wouldn't the recent winners keep leading? Sohn's answer had more to do with the people who owned those winners than with a change in their businesses. If the broader market corrected, investors needing cash could sell what had made them money. Lilly might face some of the same profit-taking as the big technology names. That would give the less popular parts of health care a chance to gain ground. He was more cautious about extending the argument to small biotech companies, which he considered particularly sensitive to interest rates.

An absolute high wouldn't settle the relative argument

Later, Patrick Dunuwila brought the discussion back to Strazza’s chart. XLV could break out of its price range while continuing to fall behind the S&P 500. Strazza pointed to 2020 and 2021: health care had gained substantially in dollars, yet its relative trend had declined steadily. An investor who bought the fund and an investor who switched into the fund from the S&P could have judged the same rally very differently.

Sohn had found the comparison somewhat stronger when both health care and the broader index were equally weighted. Giving every stock the same weight reduced the influence of the very largest companies. Strazza preferred to pay attention to what was driving the sector. Strength in medical devices, for instance, would tell him something different from a rally concentrated in the biggest drug companies.

The index was strong; fewer stocks were keeping up

The disagreement came as Parets was questioning the reach of the U.S. rally. The three-month gain in the S&P 500 and the index's distance above its 200-day average both ranked in the top historical quartile on Sohn's scatterplot. He read that as favorable for the following year. But only about 59% of stocks on the breadth measure he cited were above their 50-day averages, even with the index close to a new high.

Those numbers gave Sohn room for two different time horizons. He thought the next one to three months could be bumpy without dislodging the longer advance. Parets said he already owned out-of-the-money March puts on the S&P and Nasdaq. Sohn could see the logic of that defined-risk trade even though he still liked the longer cycle. For a manager required to stay long, he preferred looking for relative strength in health care to counting on utilities to provide shelter while higher rates were working against them.

Questions and answers

#

Questions answered in the original 2024-02-06 episode.

Which health care companies caught Todd Sohn’s attention?

He named Abbott and Medtronic in equipment and Danaher in life sciences. Their charts had begun improving while most of the attention remained on Lilly.

Link to this answer

How could XLV rise and still underperform?

Its price could go up while the S&P 500 gained more. Strazza said that had happened in 2020 and 2021, and a new XLV high alone wouldn't prove the sector was leading.

Link to this answer

Why did Sohn consider a setback possible despite strong momentum?

The index had risen sharply, but only about 59% of stocks in the breadth measure were above their 50-day averages. He thought that divergence mattered more over the next few months than for the year ahead.

Link to this answer

Adapted by Stock Market TV Editorial from the original video. Source date: . Article published: .